Gender-and obesity-specific effect of apolipoprotein C3 gene (APOC3) 482C>T polymorphism on triglyceride concentration in Turkish adults

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 2, 2012, Pages 285-292

  Coban, Neslihan ^a   Onat, Altan ^b   Guclu Geyik, Filiz ^a   Komurcu Bayrak, Evrim ^a   Sansoy, Vedat ^c   Hergenc, Gulay ^d   Can, Günay ^b   Erginel Unaltuna, Nihan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

apolipoprotein C3 482C < T polymorphism; fasting triglyceride; gender difference; obesity; Turkish population

Indexed keywords

APOLIPOPROTEIN C3; TRIACYLGLYCEROL;

ADULT; ALLELE; APOC3 GENE; ARTICLE; CARDIOMETABOLIC RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GENDER; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC);

APOLIPOPROTEIN C-III; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; SEX FACTORS; TRIGLYCERIDES; TURKEY;

EID: 84860511974     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.747     Document Type: Article

References (37)

1. Sarwar N, Danesh J, Eriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007;114:450-8. (Pubitemid 46184196)
2. Onat A, Sari I, Yazici M, Can G, Hergenç G, Avci GŞ. Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol 2006;108:89-95. (Pubitemid 43324912)
3. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism. Functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol 1999;19:472-84. (Pubitemid 29135144)
4. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995-1003.
5. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci 2008;114:611-24. (Pubitemid 351589061)
6. Karathanasis SK. Apolipoprotein multigene family: tandem organi zation of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci USA 1985;82:6374-8. (Pubitemid 16230515)
7. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining serum triglycerides. Hum Mol Genet 2002;11:3039-46. (Pubitemid 35414817)
8. Waterworth DM, Talmud PJ, Bujac SR, Fisher RM, Miller GJ, Humphries SE. The contribution of apoCIII gene variants to the determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol 2000;20:2663-9.
9. Waterworth DM, Talmud PJ, Humphries SE, Wicks PD, Sagnella GA, Strazzullo P, et al. Variable effects of the apoCIII C-482T variant on insulin, glucose and triglyceride levels in different ethnic groups. Diabetalogia 2001;44:245-8. (Pubitemid 32156211)
10. Waterworth DM, Hubacek JA, Pitha J, Kovar J, Poledne R, Humphries SE, et al. Serum levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOC1-APOE cluster. J Lipid Res 2000;41:1103-9. (Pubitemid 30483015)
11. Waterworth DM, Talmud PJ, Luan J, Flavell DM, Byrne CD, Humphries SE, et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 2003;1637:200-6. (Pubitemid 36407770)
12. Niculescu LS, Vladica M, Sima AV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun 2010;391:587-91.
13. Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS, Yusuf S, et al. Association between the-455T < C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. BMC Med Genet 2007;8:80.
14. Yamada Y, Ichihara S, Izawa H, Tanaka M, Yokota M. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol Genet Metab 2004;81:282-90. (Pubitemid 38429991)
15. Ruiz-Narvaez EA, Sacks FM, Campos H. Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. Am J Clin Nutr 2008;87:1932-8. (Pubitemid 351872661)
16. Fiegenbaum M, de Andrade FM, Hutz MH. Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes. Clin Chim Acta 2007;380:175-81. (Pubitemid 46498054)
17. Onat A, Hergenç G, Ayhan E, Uǧur M, Kaya H, Tuncer M, et al. Serum apolipoprotein C-III in high-density lipoprotein: A key dia-betogenic risk factor among Turks. Diabet Med 2009;26:981-8.
18. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10. (Pubitemid 32429589)
19. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
20. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). J Am Med Assoc 2001;285: 2486-97.
21. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
22. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191:182-90. (Pubitemid 46237629)
23. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 2005;54:664-71. (Pubitemid 40322068)
24. Atzmon G, Rincon M, Schechter CB, Shuldiner AR, Lipton RB, Bergman A, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006;4:e113.
25. Espino-Montoro A, Barrios-Artillo M, López-Chozas JM, Cayuela A, Stiefel P, Villar J. Influence of polymorphism (RFLP-sstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients: interaction between gender and genetic polymorphism. Nutr Metab Cardiovasc Dis 2003;13:194-201. (Pubitemid 38569434)
26. Martin S, Nicaud V, Humphries SE, Talmud PJ, EARS group. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003;1637:217-25. (Pubitemid 36407772)
27. Guettier JM, Georgopoulos A, Tsai M Y, Radha V, Shanthirani S, Deepa R, et al. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 2005;90:1705-11. (Pubitemid 40464041)
28. Couillard C, Vohl MC, Engert JC, Lemieux I, Houde A, Almeras N, et al. Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men. J Lipid Res 2003;44:986-93. (Pubitemid 37279658)
29. Talmud PJ, Berglund L, Hawe EM, Waterworth DM, Isasi CR, Deckelbaum RE, et al. Age-related effects of genetic variation on lipid levels: The Columbia University BioMarkers Study. Pediatrics 2001;108:E50.
30. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;362:1082-9.
31. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011;53:467-74.
32. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249, 796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-48.
33. Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet 2010;42: 949-60.
34. Ng MC, Park KS, Oh B, Tam CH, Cho YM, Shin HD, et al. Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6719 Asians. Diabetes 2008;57:2226-33.
35. Raitakari OT, Rönnemaa T, Huupponen R, Viikari L, Fan M, Marniemi J, et al. Variation of the transcription factor 7-like 2 (TCF7L2) gene predicts impaired fasting glucose in healthy young adults: the Cardiovascular Risk in Young Finns Study. Diabetes Care 2007;30:2299-301. (Pubitemid 47359036)
36. Onat A, Can G, Yüksel H, Ayhan E, Doǧan Y, Hergenç G. An algorithm to predict risk of type-2 diabetes in Turkish adults: contribution of C-reactive protein. J Endocrinol Invest 2010; Oct 27. [Epub ahead of print]
37. Onat A, Erginel-Unaltuna N, Coban N, Ciçek G, Yüksel H. APOC3-482C < T polymorphism, circulating apolipoprotein C-III and smoking: Interrelation and roles in predicting type-2 diabetes and coronary disease. Clin Biochem 2011;44:391-6.